ATTBF ...highlights “We have the ability to ma
Post# of 74540
Posted On: 03/11/2014 9:21:01 PM
ATTBF ...highlights
“We have the ability to manufacture and market the most scientifically advanced natural therapeutic formulas based on proprietary technologies through multiple distribution channels,” Withrow says.
The company licenses and markets proprietary ingredients, bio-similar compounds, and patented equipment. It also provides consulting services to North America's medicinal and adult marijuana markets via its wholly owned subsidiaries and seeks to utilize its Grow, Dry, Extract, Refine, and Sell model (known as GDERS) to produce pharmaceutical-grade phyto compounds with its ultimate goal of taking the lead in the emergent botanical drug market.
Its strategy involves growing cannabis with its proprietary indoor mass farming systems, drying it with unique low temperature drying systems to enhance quality, extracting the active ingredients, refining the product, and selling it around the world. The company has two Marijuana for Medical Purposes Regulations (MMPR) applications in, and is looking to becoming one of the few licensed producers of cannabis in Canada that is publicly traded.
Meanwhile, in the U.S., the company’s subsidiary, Biocube Systems, provide growers with an energy- and space-efficient cultivation system that generates high yields, enabling them to produce low-cost pharmaceutical-grade product. The subsidiary has just closed on acquiring the proprietary formulas from Green Gro Garden Supplies Ltd. and will build its customer base by marketing.
“We're positioned perfectly to capitalize on this rare opportunity. We've assembled everything needed to be at the forefront of the industry.”
Indeed, among Abattis' impressive roster of assets are 15 proprietary formulas, proprietary Flash Freeze Extraction equipment, two patent applications and one provisional application, as well as a five-year contract with a Canadian distributor, and exclusive worldwide rights to Mass Growing Systems used to construct controlled indoor pharma grade growing environments.
It also has a lease on a $13 million dollar Botanical Drug Facility in Quebec, fully equipped to cut costs by using the only LED made in the US that it is currently testing with the manufacturer.
“We have the ability to manufacture and market the most scientifically advanced natural therapeutic formulas based on proprietary technologies through multiple distribution channels,” Withrow says.
The company licenses and markets proprietary ingredients, bio-similar compounds, and patented equipment. It also provides consulting services to North America's medicinal and adult marijuana markets via its wholly owned subsidiaries and seeks to utilize its Grow, Dry, Extract, Refine, and Sell model (known as GDERS) to produce pharmaceutical-grade phyto compounds with its ultimate goal of taking the lead in the emergent botanical drug market.
Its strategy involves growing cannabis with its proprietary indoor mass farming systems, drying it with unique low temperature drying systems to enhance quality, extracting the active ingredients, refining the product, and selling it around the world. The company has two Marijuana for Medical Purposes Regulations (MMPR) applications in, and is looking to becoming one of the few licensed producers of cannabis in Canada that is publicly traded.
Meanwhile, in the U.S., the company’s subsidiary, Biocube Systems, provide growers with an energy- and space-efficient cultivation system that generates high yields, enabling them to produce low-cost pharmaceutical-grade product. The subsidiary has just closed on acquiring the proprietary formulas from Green Gro Garden Supplies Ltd. and will build its customer base by marketing.
“We're positioned perfectly to capitalize on this rare opportunity. We've assembled everything needed to be at the forefront of the industry.”
Indeed, among Abattis' impressive roster of assets are 15 proprietary formulas, proprietary Flash Freeze Extraction equipment, two patent applications and one provisional application, as well as a five-year contract with a Canadian distributor, and exclusive worldwide rights to Mass Growing Systems used to construct controlled indoor pharma grade growing environments.
It also has a lease on a $13 million dollar Botanical Drug Facility in Quebec, fully equipped to cut costs by using the only LED made in the US that it is currently testing with the manufacturer.
(0)
(0)Scroll down for more posts ▼